Halozyme Therapeutics Inc [HALO] stock is trading at $64.47, up 1.61%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The HALO shares have gain 4.20% over the last week, with a monthly amount drifted -7.94%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Halozyme Therapeutics Inc [NASDAQ: HALO] stock has seen the most recent analyst activity on December 04, 2025, when Goldman downgraded its rating to a Sell but kept the price target unchanged to $56 for it. Previously, Leerink Partners upgraded its rating to Market Perform on October 14, 2025, and kept the price target unchanged to $70. On August 06, 2025, upgrade upgraded it’s rating to Overweight but maintained its price target of $75 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight but $62 remained the price target by the analyst firm on May 14, 2025. Leerink Partners downgraded its rating to Underperform for this stock on May 13, 2025, but kept the price target unchanged to $47. In a note dated October 07, 2024, Wells Fargo downgraded an Equal Weight rating on this stock and boosted its target price from $58 to $62.
Halozyme Therapeutics Inc [HALO] stock has fluctuated between $46.26 and $79.50 over the past year. Currently, Wall Street analysts expect the stock to reach $73.83 within the next 12 months. Halozyme Therapeutics Inc [NASDAQ: HALO] shares were valued at $64.47 at the most recent close of the market. An investor can expect a potential return of 14.52% based on the average HALO price forecast.
Analyzing the HALO fundamentals
Halozyme Therapeutics Inc [NASDAQ:HALO] reported sales of 1.24B for the trailing twelve months, which represents a growth of 22.12%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at 0.59%, Pretax Profit Margin comes in at 0.6%, and Net Profit Margin reading is 0.48%. To continue investigating profitability, this company’s Return on Assets is posted at 0.27, Equity is 1.42 and Total Capital is 0.53. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 63.34 points at the first support level, and at 62.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 65.25, and for the 2nd resistance point, it is at 66.03.
Ratios To Look Out For
For context, Halozyme Therapeutics Inc’s Current Ratio is 1.59. Also, the Quick Ratio is 1.37, while the Cash Ratio stands at 0.5. Considering the valuation of this stock, the price to sales ratio is 6.10, the price to book ratio is 15.04 and price to earnings (TTM) ratio is 13.55.
Transactions by insiders
Recent insider trading involved Connaughton Bernadette, Director, that happened on Dec 01 ’25 when 829.0 shares were sold. PRESIDENT AND CEO, Torley Helen completed a deal on Dec 01 ’25 to sell 16569.0 shares. Meanwhile, PRESIDENT AND CEO Torley Helen sold 20000.0 shares on Nov 12 ’25.
